Marksans Pharma gets 4 USFDA observations for Goa facility

10 Apr 2017 Evaluate

Marksans Pharma manufacturing facility at Verna, Goa has been audited by the United States Food and Drug Administration (USFDA) from April 3-7, 2017. At the end of the inspection, there were 4 observations given under form 483. The company has already started addressing the same and is confident of satisfying the FDA within the stipulated time.

Further, the USFDA has also granted final approval of the Abbreviated New Drug Application for Dutasteride Soft Gelatin Capsules 0.5 mg, which is therapeutically equivalent to the reference listed drug (RLD), Avodart Capsules, 0.5 mg of GlaxoSmithKline. Dutasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. The company will launch the product immediately.

Marksans Pharma is engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.


Marksans Pharma Share Price

158.05 2.10 (1.35%)
14-May-2024 12:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1538.50
Dr. Reddys Lab 5920.00
Cipla 1372.80
Zydus Lifesciences 988.00
Lupin 1643.35
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.